Otolaryngology Doctors in Lynchburg, VA Accepting Medicare

7 Otolaryngology doctors found. Showing 1 - 7

Dr. Joseph Lynn Hutchison, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2321 Atherholt Rd, Lynchburg, VA 24501 Phone: 434-947-3993    Fax: 434-846-3992

Dr. Samkon K Gado, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2321 Atherholt Rd, Lynchburg, VA 24501 Phone: 434-947-3993    Fax: 434-947-3992

Indre Lithyouvong, PA-C Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2321 Atherholt Rd, Lynchburg, VA 24501 Phone: 434-947-3993

Dr. James Russell Hengerer, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2321 Atherholt Rd, Suite B, Lynchburg, VA 24501 Phone: 434-947-3993    Fax: 434-847-2941

Dr. Timothy Courville, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2321 Atherholt Rd, Lynchburg, VA 24501 Phone: 434-947-3993    Fax: 434-947-3992

Sam Meshkinfam, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2321 Atherholt Rd, Suite B, Lynchburg, VA 24501 Phone: 434-947-3993    Fax: 434-947-3992

Dr. Andrea E.p. Kittrell, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3029 Old Forest Rd, Lynchburg, VA 24501 Phone: 434-455-7999    Fax: 434-455-7997

News Archive

Addressing the exclusion of mental health from the MDGs

PRI's "The World" highlights the state of mental health care in Uganda in an examination of how the exclusion of mental health from the Millennium Development Goals (MDGs) has, according to some advocates, held back mental health as a global health issue. Julius Kayiira, director of Mental Health Uganda, an organization that provides social support, job training and care to people with mental illness, "says organizations like his face an enormous funding gap, and he blames that gap, in part, on the United Nations," according to "The World."

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

New genetic risk factor for Parkinson's disease identified

An international team of doctors and human geneticists has identified a new genetic risk factor for Parkinson's disease. The institutions involved in the study were the Institute of Human Genetics of Helmholtz Zentrum München and Technische Universität München, the Neurological Clinic of Ludwig-Maximilians-Universität Munich (LMU) and the Mitochondrial Research Group of Newcastle University, Newcastle upon Tyne, UK.

Cobalt Pharmaceuticals receives Notice of Compliance from Health Canada to market Atorvastatin Calcium Tablets

Watson Pharmaceuticals, Inc. today announced that its subsidiary Cobalt Pharmaceuticals has received a Notice of Compliance from Health Canada to market Atorvastatin Calcium Tablets in the 10, 20, 40 and 80 mg strengths. Watson has initiated shipments of this product.

Final days of health law's open enrollment marked by stepped up outreach efforts

News outlets detail the various strategies that are being employed to encourage more people to sign-up for coverage. Insurers are paying for ads and supporting the work of grassroots organizations. Meanwhile, students are volunteering and navigators are staying busy.

Read more Medical News

› Verified 8 days ago